| Objective: By observing the impact of berberine on type 2 diabetic rats inblood glucose, blood lipids, blood pressure, insulin sensitivity index and the aortic disease solutions, to assess their impact of treatment of type 2 diabetes mellitus; By detecting CRP, IL-6, TNF-αand lipid Adiponectin, to study the mechanism of its therapeutic effect preliminary. Method : 70 healthy adult male SD rats were placed in an environment of free drinking water for 1 week. By random number table to access 10 rats for normal controls and fed a standard diet, and the remaining 60 rats given a high sugar high fat diet, 8 weeks later, to inject streptozotocin (STZ) intraperitoneally one-time by 40mg/kg body weight , 1 weeks later to measure blood pressure, rats were fasted for 12h, the measuring blood glucose, blood lipids, blood insulin, and calculating insulin sensitivity index (ISI), to establish rat model of type 2 diabetes by fasting blood glucose greater than 7.0mmol / L and with decreased insulin sensitivity established. Type 2 diabetes will become the mode rats were randomly divided into 4 groups, namely Group 125mg/kg berberine, berberine 62.5mg/kg group, glibenclamide group 0.78mg/kg and the model group. Treatment group were orally administered for 4 weeks, observing and recording water intake, urine output, food intake during that time, to weigh 1 time each week. Normal control group, model group, etc. At the same time, the capacity of normal saline gavage. 4 weeks later, measuring blood pressure, weighed after 12h fasting, to kill the rats and take the blood from the heart and detect blood of fasting plasma glucose (FPG), insulin levels, IL--6, C-reactive protein, tumor necrosis factorα(TNF-α), lipids (TG, TC) test, and calculate the ISI and take pathological anatomy on the aortic arch.Results: Model rat blood sugar is 14.03±1.43mmol/L on an empty stomach , TC is promoted from 1.58±0.24 mmol/L to 2.59±0.36mmol/L, TG from contrasting 0.87±0.17 mmol/L to 1.50 ±0.21mmol/L, ISI form-5.08±0.36 to -6.56±0.37, blood pressure rises from 105.05±3.60mmHg to 110.62±4.38mmHg; Drinking water amounts: High dosages of berberine are 52.25±4.40ml of each rat, low dosages of berberine are 61.11±11.22 ml of each rat, the Glybenzcyclamide group is 51.00±10.69 ml of each rat,Comparing with model 86.63±10.80ml of each rat difference has altitude notable (P<0.01); Urine amounts: High dosages of berberine are 45.88±8.36 ml of each rat, low dosages of berberine are 53.33±12.57 ml of each rat, the Glybenzcyclamide group is 43.00±12.33ml of each rat, Comparing with model 70.13±17.02ml of each rat difference has altitude notable (P<0.01); Food and drink amounts: High dosages of berberine are 27.88±2.57g of each rat , low dosages of berberine are 26.67±1.74 g of each rat, the Glybenzcyclamide group is 25.08±1.61 g of each rat, Comparing with model 45.43±1.59 g of each rat difference has altitude notable (P<0.01); TC: High dosages of berberine are 2.27±0.23 mmol/L , low dosages of berberine are 2.29±0.24 mmol/L, Comparing with model 2.59±0.36 mmol/L difference has notable (P<0.05), the Glybenzcyclamide group is 2.57±0.32 mmol/L (P> 0.05); TG: High dosages of berberine are 1.31±0.14 mmol/L , low dosages of berberine are 1.32±0.18 mmol/L, Comparing with model 1.50±0.21 mmol/L difference has notable (P<0.05), the Glybenzcyclamide group is 1.39±0.20 mmol/L (P>0.05); On an empty stomach blood sugar: High dosages of berberine are 8.77±1.76 mmol/L , low dosages of berberine are 11.74±1.05 mmol/L , the Glybenzcyclamide group is 6.14±1.41 mmol/L , Comparing with model 14.36±3.21 mmol/L difference has notable (P<0.01 and P<0.05) except the low dosages of berberine; ISI: High dosages of berberine are -6.17±0.31, low dosages of berberine are -6.67±0.22, the Glybenzcyclamide group is -5.45±0.35, Comparing with model -6.93±0.47 difference has altitude notable (P<0.01) except the low dosages of berberine; The aorta bends , the model group rat arterial bast cell arranges loose, middle film fibre organization and smooth muscle cell have being unlike degree hyperplasia, the compatriot inner is visible fall apart in fat vacuole, Glybenzcyclamide forms the rat , berberine. IL-6: High dosages of berberine are 37.25±3.10pg/ml , low dosages of berberine are 43.17±3.23pg/ml , the Glybenzcyclamide group is 34.77±2.53pg/ml , Comparing with model 52.47±2.82pg/ml difference has notable (P<0.01); TNF-α: High dosages of berberine are 1.45±0.27ng/ml, low dosages of berberine are 1.46±0.26ng/ml, the Glybenzcyclamide group is 1.44±0.18ng/ml , Comparing with model 1.71±0.22ng/ml difference has notable (P<0.05); CRP: High dosages of berberine are 8.37±2.51μg/ml, low dosages of berberine are 9.12±2.54μg/ml, the Glybenzcyclamide group is 7.72±2.10μg/ml, Comparing with model 14.23±1.38μg/ml difference has notable (P<0.01); ADI: High dosages of berberine are 14.87±1.20μg/ml, low dosages of berberine are 10.98±1.14μg/ml, the Glybenzcyclamide group is 10.94±1.97μg/ml, Comparing with model 9.08±1.52μg/ml difference has notable (P<0.01and P<0.05).Conclusion: By high-sugar high-fat diet for 8 weeks, and then by the intraperitoneal injection of low-dose streptozotocin, you can create with type 2 diabetes rat model. Berberine in treatment of type 2 diabetic rats, the rats drink more, more food, more urine, significant improvement in symptoms such as weight loss, blood sugar, blood pressure, blood lipids significantly decreased aortic lesions improved, suggesting their apparent control 2 diabetes mellitus and its complications the role. Berberine in treatment of type 2 diabetic rats, the serum CRP, IL-6, TNF-αlevels were significantly lower adiponectin levels were significantly increased, suggesting that the control mechanism of type 2 diabetes may be related to the impact of the level of serum inflammatory factors .
|
PDF Full Text Request